Topic: neurological disorders
Celgene launched a $60 million collaboration with Skyhawk Therapeutics to develop small molecules targeting RNA mis-splicing in neurological diseases.
Biogen is paying a $375 million fee and splurging $625 million on Ionis’ stock for a chance to pick up a series of neurological antisense drugs.
Roche snapped up a remyelinating drug candidate for multiple sclerosis from an alliance with Versant that also spawned startup Pipeline Therapeutics.
Perennial biotech dealmaker Takeda is at it again, striking a new pact with Wave Life Sciences with a focus on a series of neurological disorders.
Syndesi begins life with a $20.9 million infusion, to carry a SV2A modulator through early proof of concept.
Biogen is paying $10 million upfront and committing to up to $207 million more in milestones to buy the IND-ready oral SINE compound.
Disarm has poached Big Pharma executive Thomas Engber, Ph.D., as its new SVP and head of neuropharmacology and translational sciences.
Synlogic and Ginkgo Bioworks have inked a deal to develop treatments for liver and neurological disease by targeting the gut.
Shares in Acorda Therapeutics are sliding following the news that the company’s Parkinson’s drug has been linked to a potentially fatal side effect.
Scientists have discovered key stem cells that help the gecko tail regenerate—insights that may spur therapies for people with spinal cord injuries.